Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PTN
PTN logo

PTN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Palatin Technologies Inc (PTN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
18.500
1 Day change
-6.12%
52 Week Range
31.000
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Palatin Technologies Inc (PTN) is not a strong buy for a beginner investor with a long-term strategy at this moment. The lack of significant positive catalysts, weak financial performance, and no clear trading signals suggest holding off on this investment for now.

Technical Analysis

The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 45.961, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 20.334, R1: 22.442, S1: 18.227, R2: 23.744, S2: 16.924. The stock is trading near its pivot point, suggesting no strong directional trend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
6

Positive Catalysts

  • NULL identified. No recent news or significant insider or hedge fund activity. The stock has a 40% chance to gain 1.04% in the next day and 2.71% in the next week, but these are not strong enough catalysts.

Neutral/Negative Catalysts

  • No recent congress trading data or influential figure activity. No significant trading trends from insiders or hedge funds.

Financial Performance

In 2026/Q2, revenue remained flat YoY at 116,036. Net income improved YoY by 197.40% but remains negative at -7,263,861. EPS dropped significantly by -51.69% YoY to -2.86. Gross margin remained stable at 100%. Overall, financials are weak and do not support a strong buy case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available for evaluation.

Wall Street analysts forecast PTN stock price to rise
1 Analyst Rating
Wall Street analysts forecast PTN stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.705
sliders
Low
50
Averages
50
High
50
Current: 19.705
sliders
Low
50
Averages
50
High
50
Laidlaw
NULL -> Buy
initiated
$60
AI Analysis
2025-12-12
Reason
Laidlaw
Price Target
$60
AI Analysis
2025-12-12
initiated
NULL -> Buy
Reason
Laidlaw initiated coverage of Palatin with a Buy rating and $60 price target. Palatin (PTN) is a clinical stage biotech company focusing on developing melanocortin receptor based therapeutics, the analyst tells investors in a research note. The firm believes the company's offerings are better than Rhythm Pharmaceuticals' (RYTM) setmelanotide and are very competitive against their next generation follow-on products.
Jefferies
Buy
downgrade
$21 -> $20
2025-12-11
Reason
Jefferies
Price Target
$21 -> $20
2025-12-11
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Pattern Group to $20 from $21 and keeps a Buy rating on the shares. The firm recommends staying selective across Internet stocks, as incremental investments could limit margin expansion and concerns around AI disintermediation could limit multiple appreciation, the analyst tells investors in the firm's "2026 Internet Playbook" note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PTN
Unlock Now

People Also Watch